BRCA2 and breast carcinoma: This work is significant for Black breast cancer patients, who may require CLIA-certified genetic testing because it employs comprehensive sequencing to identify more than the three Ashkenazi Jewish founder variants in BRCA1 and BRCA2 assessed by some DTC genetic tests.